Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the first planned interim analysis, which included consideration of pre-specified criteria for futility. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.   The futility analy...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news